Review top news and interview highlights from the week ending August 18, 2023.
Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
Bluebird's gene-edited cell therapy has a PDUFA date of December 20, 2023.
The senior partner at Retina Vitreous Associates Medical Group discussed new findings from the AAVIATE study of RGX-314.
The formal hold comes approximately 2 months after Seattle Children’s paused the trial in accordance with the clinical study protocol stopping rules.
The adjunct clinical assistant professor, ophthalmology, Keck School of Medicine, University of Southern California discussed unmet needs with the current treatment landscape for DR.
The partial clinical hold was originally placed in June 2023 in relation to the death of a patient participating in the trial.